?Product Overview?
Apalutamide (CAS: 956104-40-8) is a second-generation ?nonsteroidal androgen receptor (AR) inhibitor? with the molecular formula ?C??H??F?N?O?S? (MW: 477.44). It selectively blocks AR signaling, inhibiting tumor growth in prostate cancer by preventing androgen-mediated gene transcription?23. This white to off-white crystalline powder is primarily used for treating ?non-metastatic castration-resistant prostate cancer (NM-CRPC)? and ?metastatic castration-sensitive prostate cancer (mCSPC)??.

? ?Key Advantages?
? ?High Purity?: ≥98% (HPLC/GC tested), ensuring pharmaceutical-grade reliability?12.
? ?Potent AR Inhibition?: Demonstrates IC?? of 16 nM for AR binding, effectively suppressing tumor progression?.
? ?Thermal Stability?: Stable under recommended storage conditions (2-8°C, dry, and protected from light)?.

?? ?Application Fields?

• ?Oncology?: First-line therapy for NM-CRPC and mCSPC, improving survival rates in clinical trials?.

• ?Clinical Research?: Key compound for studying resistance mechanisms in hormone-sensitive cancers?.

• ?Drug Development?: Intermediate for synthesizing advanced AR-targeted therapies?.

?? ?Quality Certifications?

• Manufactured in ?GMP-certified facilities?, compliant with ?USP/EP standards??.

• Rigorous QC via ?HPLC, NMR, and mass spectrometry? for batch consistency?.

• Complies with ?MSDS guidelines? for safe handling and storage?.

?? ?Market Insights?
The global prostate cancer therapeutics market is projected to reach ?20.4B by 2030**‌ (CAGR 8.2%), driven by rising prevalence and demand for targeted therapies. Apalutamide’s role in the ‌**1.5B NM-CRPC treatment segment? highlights its commercial relevance?.